II.a

Pulmonary edema, noncardiogenic (NCPE)

(Fr: OAP non cardiogénique). A.k.a. permeability edema. Typically acute and florid. Less often subaute/benign. PE may complicate drug overdoses. May accompany anaphylactic shock (PMID 29086053). May cause the ARDS picture. Drug-induced pulmonary edema cases generally have an acute or sudden onset, and are noncardiac (normal heart US and wedge pressure when measured) (NCPE). Transient fleeting pulmonary infiltrates were often reported as 'acute allergic pulmonary edema'. Hyperacute PE cases are sometimes called 'flash pulmonary edema' (see under IIi). Severe NCPE cases may exhibit the characteristic of ARDS (PMID 3532567, 15062601, 7555128, 1914570). The diagnosis of NCPE is raised when timing of the reaction is shortly (seconds to minutes) following administration of the causal drug or agent. NCPE is also a feature of anaphylaxis episodes (PMID 24376328). Patients with pulmonary hypertension are prone to the development of vasoldilator-induced NCPE (see under NO and other pulmonary vasodilator drugs). NCPE will generally relapse if the patient is reexposed to the drug. Note: overzealous administration of i.v. fluids or blood to a patient whose cardiocirculatory system cannot accomodate it may cause overload (hydrostatic) pulmonary edema (IIh) or TACO

Last update : 06/04/2018
 

Causative drugs

200

Aspirin (Salicylate-ASA)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.y VIII - Upper, central, large airway involvement
VIII.y - Sinonasal discharge, -blockage, -obstruction
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.q X - Systemic conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
3

Beta-blockers

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.w VI - Pulmonary vasculopathy
VI.w - Worsening of preexisting PHTn
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.y X - Systemic conditions, syndromes and reactions
X.y - Subclinical ANA positivity
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.af XI - Miscellaneous
XI.af - Refractoriness to epineprine in case of anaphylaxis
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
3